Zacks Investment Research
16 Sept 2026, 14:55 UTC · 1h ago
Verdict
Headline takes no side. We score PMVP +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
PMV Pharmaceuticals' 50-day simple moving average has crossed above its 200-day simple moving average, forming a 'golden cross'.
Priced intechnical analysis of existing price history
More positive than 77% of claims this week
There have been 2 upward earnings estimate revisions and zero downward revisions for PMVP over the past 60 days.
Priced in
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
So whatPositive revision trends often lead to an EPS beat in the next quarterly print.
More positive than 65% of claims this week
PMVP's stock price has increased by 9.7% over the past four weeks.
Priced inanalysis of past 4 weeks price action
More positive than 46% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company shows a bullish 'golden cross' technical pattern, positive earnings outlook, and upward estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
+8.8%
Price agrees with the score
$1.48 vs $1.36 close before publication (Sep 15) · not market-adjusted
PMVP chart →
